Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus pembrolizumab and chemotherapy for first-line CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
NL-OMON59126Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Zolbetuximab + pembrolizumab + CAPOX or mFOLFOX6 with Placebo + pembrolizumab + CAPOX or mFOLFOX6 (2 arms). Primary endpoint: Overall survival. Started Aug 2025; status: active, not recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON59126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59126.